{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-028305","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2023-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.403590+00:00","generated_at":"2026-06-17T04:46:24.603829+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nasdaq notifies Phoenix Biotech of MVLS non-compliance for 30 consecutive days","bullets":["Received Nasdaq letter on April 3, 2023; common stock MVLS below $50M minimum for 30 consecutive trading days.","Has 180 days (until October 2, 2023) to regain compliance under Listing Rule 5810(c)(3)(C).","To regain compliance, MVLS must close at or above $50M for at least ten consecutive business days.","If not compliant by deadline, may transfer to Nasdaq Capital Market or face delisting with appeal rights.","Deficiency notice has no immediate effect on listing or trading; Company monitoring options."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-028305","json":"https://secwatch.observer/filing/0001213900-23-028305.json","markdown":"https://secwatch.observer/filing/0001213900-23-028305.md","text":"https://secwatch.observer/filing/0001213900-23-028305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023028305/0001213900-23-028305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023028305/ea176568-8k_phoenix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:46:24.603829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2892e4279992d9fb156b8bacdd5ae8e66f68f25","claim":"CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).","evidence_excerpt":"April 3, 2023, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “ Company ”), received a letter (the “ Letter ”) from the staff at The Nasdaq Global Market (“ Nasdaq ”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Letter, the Company’s common stock had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“ MVLS ”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s common stock on Nasdaq. The Letter is only a notification of deficiency, not","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023028305/0001213900-23-028305-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5450(b)(2)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}